Hematology/Oncology

Top Story

Top Takeaways from ASH: Benefits, drawbacks of Factor VIII products require discussion with patients

Top Takeaways from ASH: Benefits, drawbacks of Factor VIII products require discussion with patients
May 26, 2016

The multicenter, randomized Survey of Inhibitors in Plasma-Product Exposed Toddlers, or SIPPET study, presented at the ASH Annual Meeting and Exposition, which demonstrated that recombinant Factor VIII products may lead to a 1.87-fold increased risk for the development of an inhibitor compared with plasma-derived products among patients with severe hemophilia A, represents “significant” results that impact the therapeutic choices made about the different Factor VIII products.

“This is quite a significant finding. Inhibitors are a very serious problem for patients with hemophilia,” according to Ulrike M. Reiss, MD, associate faculty member and director of clinical hematology and the hemophilia treatment center at St. Jude Children’s Research Hospital. “They basically neutralize any infused factor and, therefore, there is no optimal way of treating, and stopping, bleeding.”

FDA News

FDA approves Afstyla to treat patients with hemophilia A

May 26, 2016
The FDA approved antihemophilic factor (recombinant), single chain to treat adults and children with hemophilia A.Antihemophilic factor (recombinant), single chain…
Ask the Experts

What is a cyst?

May 26, 2016
A cyst is a closed sac with a defined membrane and division on the nearby tissue. Cysts may contain fluid, air or semi-solid material. There are various types of…
In the Journals

Physical activity associated with lower risks of 13 cancers

May 26, 2016
Leisure-time physical activity was associated with lower risks for 13 out of 26 cancers included in an investigation published in JAMA Internal Medicine. Steven C
In the Journals

Catheter-directed thrombolysis reduces post-thrombotic syndrome after DVT

May 26, 2016
Catheter-directed thrombolysis appeared associated with a persistent risk reduction for post-thrombotic syndrome among patients with extensive proximal deep vein…
More News Headlines »
CME

Updates from Vienna 2015 – Highlights in Hematologic Malignancies

This activity is supported by an educational grant from Genentech, Inc.

The management of patients with hematologic malignancies—from diagnosis to treatment decisions—can represent a…
More »
Video
Meeting News Coverage

VIDEO: Expert discusses controversies in lung cancer screenings

May 13, 2016
More »
Featured
AACR Annual Meeting

AACR Annual Meeting

CME

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty-five percent of lung cancers are non-small…
More »
Current Issues
View the Current Issue
HemOnc Today
morganatic-roan